Telix Pharmaceuticals Limited today announced the successful completion of CUPID, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer.
TLX592 (Ac-PSMA-RADmAb®) is Telix’s investigational next generation targeted alpha therapy (TAT) for the treatment of prostate cancer, utilizing the proprietary RADmAb® engineered antibody technology. The CUPID study demonstrated accelerated blood kinetics compared to standard antibodies while maintaining favorable biodistribution and hepatic clearance. No serious adverse events were observed in the study.
Dr. David N. Cade, Telix’s Group Chief Medical Officer, expressed excitement over the results and announced plans to advance TLX592 into a therapeutic Phase I/II study in the second half of 2024. The study aims to address the unmet need for novel targeting platforms in prostate cancer therapy.
Telix’s commitment to developing innovative radiopharmaceuticals and addressing significant medical needs in oncology and rare diseases remains steadfast. With TLX592’s promising results, Telix is poised to make significant progress in prostate cancer treatment.
Telix Pharmaceuticals continues to lead the way in the development of groundbreaking therapies, bringing hope to patients and enhancing the field of oncology.
